Compare AVXL & RGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | RGCO |
|---|---|---|
| Founded | 2004 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.1M | 233.9M |
| IPO Year | 2013 | 2005 |
| Metric | AVXL | RGCO |
|---|---|---|
| Price | $3.40 | $22.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $22.00 | ★ $22.70 |
| AVG Volume (30 Days) | ★ 2.0M | 7.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.88% |
| EPS Growth | N/A | ★ 11.21 |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $95,334,212.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $2.89 |
| P/E Ratio | ★ N/A | $47.77 |
| Revenue Growth | N/A | ★ 12.63 |
| 52 Week Low | $2.61 | $19.68 |
| 52 Week High | $13.99 | $24.00 |
| Indicator | AVXL | RGCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 52.37 |
| Support Level | $2.93 | $20.93 |
| Resistance Level | $4.88 | $22.80 |
| Average True Range (ATR) | 0.18 | 0.72 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 98.62 | 47.96 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.